Tuberculosis in Solid Organ Transplantation: Insights from TB Endemic Areas

The incidence of tuberculosis (TB) is many fold higher in transplant recipients than in the general population with the highest risk in first year post-transplant. The purpose of this review is to describe the epidemiology, clinical characteristics, management, and outcomes of TB in organ transplant recipients from TB endemic regions and highlight the challenges faced in their management.

Recent Findings

TB can be increasingly difficult to diagnose and manage in transplant recipients. Clinical manifestations are often atypical leading to delay in diagnosis and available diagnostic modalities are limited in their ability to accurately detect TB. Moreover, the treatment of TB is particularly difficult owing to drug–drug interactions with post-transplant medications. Hence, the focus of recent research has been identification and treatment of latent TB infection pre-transplant.

Summary

The prevalence of TB in transplant recipients is reportedly 12% in TB endemic countries compared to 5% in developed countries. The risk is greatest among transplant recipients with residence in a country with high TB burden. The clinical presentation can vary from the classic symptoms to unusual extrapulmonary manifestations, particularly involvement of genitourinary tract in renal transplant recipients. The first-line treatment is similar to that for immunocompetent patients but requires greater vigilance in monitoring of side effects, particularly hepatotoxicity. Longer treatment duration may be needed in those in whom a first-line regimen could not be used or those with drug-resistant TB. All transplant recipients should be screened for latent TB infection (LTBI) and given prophylaxis if found to have evidence of LTBI.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic €32.70 /Month

Buy Now

Price includes VAT (France)

Instant access to the full article PDF.

Rent this article via DeepDyve

Similar content being viewed by others

Prevention and Treatment of Mycobacterial Infections

Chapter © 2019

Mycobacterium tuberculosis in Transplantation

Chapter © 2020

Mycobacterium tuberculosis in Transplantation

Chapter © 2021

Data Availability Statement

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

Availability of Data and Materials

All data presented in this study is included in this published article.

References

  1. Abad CL, Razonable RR. Prevention and treatment of tuberculosis in solid organ transplant recipients. Expert review of anti-infective therapy. 2020;18(1):63–73. https://doi.org/10.1080/14787210.2020.1704255. ArticleCASPubMedGoogle Scholar
  2. Abad CLR, Razonable RR. Donor derived Mycobacterium tuberculosis infection after solid-organ transplantation: a comprehensive review. Transplant infectious disease: an official journal of the Transplantation Society. 2018;20(5):e12971. https://doi.org/10.1111/tid.12971. ArticleCASGoogle Scholar
  3. Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 1998;27(5):1266–77. https://doi.org/10.1086/514993. ArticleCASGoogle Scholar
  4. Epstein DJ, Subramanian AK. Prevention and management of tuberculosis in solid organ transplant recipients. Infectious disease clinics of North America. 2018;32(3):703–18. https://doi.org/10.1016/j.idc.2018.05.002. ArticlePubMedGoogle Scholar
  5. Krishnamoorthy S, Kumaresan N, Zumla A. Latent tuberculosis infection and renal transplantation - diagnosis and management. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases. 2019;80s:S73-s6. doi:https://doi.org/10.1016/j.ijid.2019.01.049.
  6. Organization WH. Tuberculosis. 2020. https://www.who.int/news-room/fact-sheets/detail/tuberculosis. Accessed 11-04-2021 2021.
  7. Organization WH. Global tuberculosis report 2020. 2020. https://www.who.int/publications/i/item/9789240013131. Accessed 27-Feb-21 2021.
  8. Subramanian A, Dorman S. Mycobacterium tuberculosis in solid organ transplant recipients. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2009;9(Suppl 4):S57–62. https://doi.org/10.1111/j.1600-6143.2009.02894.x. ArticleGoogle Scholar
  9. Torre-Cisneros J, Doblas A, Aguado JM, San Juan R, Blanes M, Montejo M, et al. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2009;48(12):1657–65. https://doi.org/10.1086/599035. ArticleGoogle Scholar
  10. Liu J, Yan J, Wan Q, Ye Q, Huang Y. The risk factors for tuberculosis in liver or kidney transplant recipients. BMC infectious diseases. 2014;14:387. https://doi.org/10.1186/1471-2334-14-387. ArticleCASPubMedPubMed CentralGoogle Scholar
  11. Abad CLR, Razonable RR. Mycobacterium tuberculosis after solid organ transplantation: a review of more than 2000 cases. Clinical transplantation. 2018;32(6):e13259. https://doi.org/10.1111/ctr.13259. ArticlePubMedGoogle Scholar
  12. Hussain Z, Naqvi R, Hashmi A, Hafiz S, Naqvi A, Rizvi A. Tuberculosis in renal allograft recipients. Transplantation proceedings. 1996;28(3):1516–7. CASPubMedGoogle Scholar
  13. Sakhuja V, Jha V, Varma PP, Joshi K, Chugh KS. The high incidence of tuberculosis among renal transplant recipients in India. Transplantation. 1996;61(2):211–5. https://doi.org/10.1097/00007890-199601270-00008. ArticleCASPubMedGoogle Scholar
  14. Bumbacea D, Arend SM, Eyuboglu F, Fishman JA, Goletti D, Ison MG, et al. The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement. The European respiratory journal. 2012;40(4):990–1013. https://doi.org/10.1183/09031936.00000712. ArticlePubMedGoogle Scholar
  15. Helleberg M, Cho D, Ekenberg C, Sørensen S, Rix M, Gustafsson F, et al. Tuberculosis among patients undergoing solid organ transplantation or dialysis in a low-endemic country, 2004-2017. Tuberculosis Research and Treatment. 2020;2020:7636975. https://doi.org/10.1155/2020/7636975. ArticlePubMedPubMed CentralGoogle Scholar
  16. Sundaram M, Adhikary SD, John GT, Kekre NS. Tuberculosis in renal transplant recipients. Indian journal of urology: IJU: journal of the Urological Society of India. 2008;24(3):396–400. https://doi.org/10.4103/0970-1591.42625. ArticleGoogle Scholar
  17. Subramanian AK, Theodoropoulos NM. Mycobacterium tuberculosis infections in solid organ transplantation: guidelines from the infectious diseases community of practice of the American Society of Transplantation. Clinical transplantation. 2019;33(9):e13513. https://doi.org/10.1111/ctr.13513. ArticlePubMedGoogle Scholar
  18. Morris MI, Daly JS, Blumberg E, Kumar D, Sester M, Schluger N et al. Diagnosis and management of tuberculosis in transplant donors: a donor-derived infections consensus conference report†. American Journal of Transplantation. 2012;12(9):2288-300. doi:https://doi.org/10.1111/j.1600-6143.2012.04205.x.
  19. Meinerz G, da Silva CK, Goldani JC, Garcia VD, Keitel E. Epidemiology of tuberculosis after kidney transplantation in a developing country. Transplant infectious disease: an official journal of the Transplantation Society. 2016;18(2):176–82. https://doi.org/10.1111/tid.12501. ArticleCASGoogle Scholar
  20. Mamishi S, Pourakbari B, Moradzadeh M, van Leeuwen WB, Mahmoudi S. Prevalence of active tuberculosis infection in transplant recipients: a systematic review and meta-analysis. Microbial pathogenesis. 2020;139:103894. https://doi.org/10.1016/j.micpath.2019.103894. ArticleCASPubMedGoogle Scholar
  21. Pai M, Kalantri S, Aggarwal AN, Menzies D, Blumberg HM. Nosocomial tuberculosis in India. Emerging infectious diseases. 2006;12(9):1311–8. https://doi.org/10.3201/eid1209.051663. ArticlePubMedPubMed CentralGoogle Scholar
  22. Nathavitharana RR, Bond P, Dramowski A, Kotze K, Lederer P, Oxley I et al. Agents of change: the role of healthcare workers in the prevention of nosocomial and occupational tuberculosis. La Presse Médicale. 2017;46(2, Part 2):e53-e62. doi:https://doi.org/10.1016/j.lpm.2017.01.014.
  23. Cookson ST, Jarvis WR. Prevention of nosocomial transmission of Mycobacterium tuberculosis* *All material in this article, with the exception of borrowed figures, tables, or text, is in the public domain. Infectious disease clinics of North America. 1997;11(2):385–409. https://doi.org/10.1016/S0891-5520(05)70362-7. ArticleCASPubMedGoogle Scholar
  24. Rahimifard N, Mahmoudi S, Mamishi S, Pourakbari B. Prevalence of latent tuberculosis infection in transplant candidates: a systematic review and meta-analysis. Microbial pathogenesis. 2018;125:401–10. https://doi.org/10.1016/j.micpath.2018.09.040. ArticlePubMedGoogle Scholar
  25. Lee J, Yew WW, Wong CF, Wong PC, Chiu CS. Multidrug-resistant tuberculosis in a lung transplant recipient. The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation. 2003;22(10):1168–73. https://doi.org/10.1016/s1053-2498(02)01189-0. ArticleGoogle Scholar
  26. Ullah K, Raza S, Ahmed P, Satti TM, Ikram A, Chaudhry QU, et al. Pulmonary tuberculosis in allogeneic stem cell transplant recipients. JPMA The Journal of the Pakistan Medical Association. 2007;57(11):567–9. PubMedGoogle Scholar
  27. Akhtar S, Naseem A, Dodani S, Naqvi R, Ahmad E, Naqvi A, et al. Tuberculosis in renal transplant recipients on isoniazid prophylaxis. European Respiratory Journal. 2016;48(suppl 60):PA2104. https://doi.org/10.1183/13993003.congress-2016.PA2104. ArticleGoogle Scholar
  28. Naqvi R, Naqvi A, Akhtar S, Ahmed E, Noor H, Saeed T, et al. Use of isoniazid chemoprophylaxis in renal transplant recipients. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association. 2010;25(2):634–7. https://doi.org/10.1093/ndt/gfp489. ArticleCASGoogle Scholar
  29. Olithselvan A, Rajagopala S, Vij M, Shanmugam V, Shanmugam N, Rela M. Tuberculosis in liver transplant recipients: experience of a South Indian liver transplant center. Liver Transplantation. 2014;20(8):960–6. https://doi.org/10.1002/lt.23903. ArticlePubMedGoogle Scholar
  30. Rashid HU, Khanam A, Islam S, Wahab MA, Iqbal KM. Experience with living donor kidney transplantation in Bangladesh. Transplantation proceedings. 1999;31(8):3112. https://doi.org/10.1016/s0041-1345(99)00739-3. ArticleCASPubMedGoogle Scholar
  31. Wu W, Yang M, Xu M, Ding C, Li Y, Xu K, et al. Diagnostic delay and mortality of active tuberculosis in patients after kidney transplantation in a tertiary care hospital in China. PloS one. 2018;13(4):e0195695. https://doi.org/10.1371/journal.pone.0195695. ArticleCASPubMedPubMed CentralGoogle Scholar
  32. Leong LY, Lin PC, Chi CY, Chou CH, Lu MC, Liao WC et al. Risk factors of tuberculosis after liver transplant in a tertiary care hospital. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. 2019. doi:https://doi.org/10.1016/j.jmii.2019.08.006.
  33. Thitisuriyarax S, Vanichanan J, Udomkarnjananun S, Townamchai N, Jutivorakool K. Risk factors and clinical outcomes of tuberculosis among kidney transplant recipients in high endemic country. Transplant infectious disease: an official journal of the Transplantation Society. 2021:e13566. doi:https://doi.org/10.1111/tid.13566.
  34. Rungruanghiranya S, Ekpanyaskul C, Jirasiritum S, Nilthong C, Pipatpanawong K, Mavichak V. Tuberculosis in Thai renal transplant recipients: a 15-year experience. Transplantation proceedings. 2008;40(7):2376–9. https://doi.org/10.1016/j.transproceed.2008.07.034. ArticleCASPubMedGoogle Scholar
  35. Hall CM, Willcox PA, Swanepoel CR, Kahn D, Van Zyl Smit R. Mycobacterial infection in renal transplant recipients. Chest. 1994;106(2):435–9. https://doi.org/10.1378/chest.106.2.435. ArticleCASPubMedGoogle Scholar
  36. Iliyasu G, Abdu A, Dayyab FM, Tiamiyu AB, Habib ZG, Adamu B, et al. Post-renal transplant infections: single-center experience from Nigeria. Transplant infectious disease: an official journal of the Transplantation Society. 2016;18(4):566–74. https://doi.org/10.1111/tid.12548. ArticleCASGoogle Scholar
  37. Ghafari A, Makhdoomi K, Ahmadpoor P, Afshari AT, Fallah MM, Rezaee K. Tuberculosis in Iranian kidney transplant recipients: a single-center experience. Transplantation proceedings. 2007;39(4):1008–11. https://doi.org/10.1016/j.transproceed.2007.03.013. ArticleCASPubMedGoogle Scholar
  38. Lopez de Castilla D, Schluger NW. Tuberculosis following solid organ transplantation. Transplant infectious disease: an official journal of the Transplantation Society. 2010;12(2):106–12. https://doi.org/10.1111/j.1399-3062.2009.00475.x. ArticleCASGoogle Scholar
  39. Shitrit D, Bendayan D, Saute M, Kramer MR. Multidrug resistant tuberculosis following lung transplantation: treatment with pulmonary resection. Thorax. 2004;59(1):79–80. CASPubMedPubMed CentralGoogle Scholar
  40. Cialente F, Grasso M, Ralli M, De Vincentiis M, Minni A, Agolli G et al. Laryngeal tuberculosis in renal transplant recipients: a case report and review of the literature. Bosnian journal of basic medical sciences. 2020;20(3):411-4. doi:https://doi.org/10.17305/bjbms.2020.4448.
  41. Schluger LK, Sheiner PA, Jonas M, Guarrera JV, Fiel IM, Meyers B, et al. Isoniazid hepatotoxicity after orthotopic liver transplantation. The Mount Sinai journal of medicine, New York. 1996;63(5-6):364–9. CASPubMedGoogle Scholar
  42. Udin Babar Z, Nasim A, Kumar S, Nazmi J, Badlani S, Nadeem A et al. A case series of multidrug resistant tuberculosis in renal transplant recipients: challenges in management from a TB endemic country. Transplant Infectious Disease.n/a(n/a):e13659. doi:https://doi.org/10.1111/tid.13659.
  43. Koh WJ, Kang YR, Jeon K, Kwon OJ, Lyu J, Kim WS, et al. Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients. The Journal of antimicrobial chemotherapy. 2012;67(6):1503–7. https://doi.org/10.1093/jac/dks078. ArticleCASPubMedGoogle Scholar
  44. Sreejith P, Jha V, Kohli HS, Rathi M, Gupta KL, Sakhuja V. Allograft and prostatic involvement in a renal transplant recipient with disseminated tuberculosis. Indian J Nephrol. 2010;20(1):40–2. https://doi.org/10.4103/0971-4065.62097. ArticleCASPubMedPubMed CentralGoogle Scholar
  45. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clinical pharmacokinetics. 2003;42(9):819–50. https://doi.org/10.2165/00003088-200342090-00003. ArticleCASPubMedGoogle Scholar
  46. Aguado JM, Herrero JA, Gavaldá J, Torre-Cisneros J, Blanes M, Rufí G, et al. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain1. Transplantation. 1997;63(9):1278–86. ArticleCASGoogle Scholar
  47. Zeng QZ, Zhang YY, Wu YJ, Zhang ZY, Zhang JN, Fu HX, et al. Frequency, risk factors, and outcome of active tuberculosis following allogeneic hematopoietic stem cell transplantation. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation. 2020;26(6):1203–9. https://doi.org/10.1016/j.bbmt.2020.02.018. ArticleCASGoogle Scholar
  48. Wu TJ, Chiang WF, Wu ST, Lin SH. Tuberculous sacroiliitis in a renal transplant recipient: a case report. Transplantation proceedings. 2013;45(7):2798–800. https://doi.org/10.1016/j.transproceed.2012.12.035. ArticlePubMedGoogle Scholar
  49. Jung JY, Joo DJ, Lee CH, Park MS, Kim YS, Kim MS, et al. Pre-transplant risk factors for tuberculosis after kidney transplant in an intermediate burden area. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease. 2012;16(2):248–54. https://doi.org/10.5588/ijtld.11.0259. ArticleCASGoogle Scholar
  50. Giacomelli IL, Schuhmacher Neto R, Nin CS, Cassano PS, Pereira M, Moreira JDS, et al. High-resolution computed tomography findings of pulmonary tuberculosis in lung transplant recipients. Jornal brasileiro de pneumologia: publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia. 2017;43(4):270–3. https://doi.org/10.1590/s1806-37562016000000306. ArticleGoogle Scholar
  51. John GT, Shankar V, Abraham AM, Mukundan U, Thomas PP, Jacob CK. Risk factors for post-transplant tuberculosis. Kidney international. 2001;60(3):1148–53. https://doi.org/10.1046/j.1523-1755.2001.0600031148.x. ArticleCASPubMedGoogle Scholar
  52. Muñoz P, Rodríguez C, Bouza E. Mycobacterium tuberculosis infection in recipients of solid organ transplants. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2005;40(4):581–7. https://doi.org/10.1086/427692. ArticleGoogle Scholar
  53. Benito N, García-Vázquez E, Horcajada JP, González J, Oppenheimer F, Cofán F, et al. Clinical features and outcomes of tuberculosis in transplant recipients as compared with the general population: a retrospective matched cohort study. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2015;21(7):651–8. https://doi.org/10.1016/j.cmi.2015.03.010. ArticleCASGoogle Scholar
  54. Ram R, Swarnalatha G, Prasad N, Dakshinamurty KV. Tuberculosis in renal transplant recipients. Transplant infectious disease: an official journal of the Transplantation Society. 2007;9(2):97–101. https://doi.org/10.1111/j.1399-3062.2006.00182.x. ArticleCASGoogle Scholar
  55. Basiri A, Hosseini-Moghaddam SM, Simforoosh N, Einollahi B, Hosseini M, Foirouzan A, et al. The risk factors and laboratory diagnostics for post renal transplant tuberculosis: a case-control, country-wide study on definitive cases. Transplant infectious disease: an official journal of the Transplantation Society. 2008;10(4):231–5. https://doi.org/10.1111/j.1399-3062.2007.00271.x. ArticleCASGoogle Scholar
  56. Ardalan MR, Shoja MM, Ghabili K. Concomitant pulmonary tuberculosis and tuberculous appendicitis in a recipient of a renal transplant: a case report. Journal of medical case reports. 2011;5:191. https://doi.org/10.1186/1752-1947-5-191. ArticlePubMedPubMed CentralGoogle Scholar
  57. Nayak S, Satish R. Genitourinary tuberculosis after renal transplantation-a report of three cases with a good clinical outcome. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2007;7(7):1862–4. https://doi.org/10.1111/j.1600-6143.2007.01853.x. ArticleCASGoogle Scholar
  58. Kirushnan B, Akhil M, Arumugam K, Ravichandran R. Esophageal tuberculosis and infected tuberculous lymphocele: unusual case presentations of tuberculosis in postrenal transplantation. Indian Journal of Transplantation. 2017;11(3):168–70. https://doi.org/10.4103/ijot.ijot_8_17. ArticleGoogle Scholar
  59. Chen SY, Wang CX, Chen LZ, Fei JG, Deng SX, Qiu J, et al. Tuberculosis in southern Chinese renal-transplant recipients. Clinical transplantation. 2008;22(6):780–4. https://doi.org/10.1111/j.1399-0012.2008.00878.x. ArticlePubMedGoogle Scholar
  60. Abdu A, Adamu B, Sani MU, Mohammed AZ, Borodo MM. Post kidney transplant tuberculosis in Nigeria: a case report. Nigerian journal of medicine: journal of the National Association of Resident Doctors of Nigeria. 2008;17(2):217–9. https://doi.org/10.4314/njm.v17i2.37388. ArticleCASGoogle Scholar
  61. Mohapatra A, Basu G, Sen I, Asirvatham R, Michael J, Pulimood A, et al. Tuberculosis in a renal allograft recipient presenting with intussusception. Indian Journal of Nephrology. 2012;22(1):52–6. https://doi.org/10.4103/0971-4065.83741. ArticleCASPubMedPubMed CentralGoogle Scholar
  62. Chen CH, Lian JD, Cheng CH, Wu MJ, Lee WC, Shu KH. Mycobacterium tuberculosis infection following renal transplantation in Taiwan. Transplant infectious disease: an official journal of the Transplantation Society. 2006;8(3):148–56. https://doi.org/10.1111/j.1399-3062.2006.00147.x. ArticleGoogle Scholar
  63. Ku SC, Tang JL, Hsueh PR, Luh KT, Yu CJ, Yang PC. Pulmonary tuberculosis in allogeneic hematopoietic stem cell transplantation. Bone marrow transplantation. 2001;27(12):1293–7. https://doi.org/10.1038/sj.bmt.1703092. ArticleCASPubMedGoogle Scholar
  64. Aguado JM, Silva JT, Samanta P, Singh N. Tuberculosis and transplantation. Microbiology spectrum. 2016;4(6). doi:https://doi.org/10.1128/microbiolspec.TNMI7-0005-2016.
  65. Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: diagnosis of tuberculosis in adults and children. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2017;64(2):111–5. https://doi.org/10.1093/cid/ciw778. ArticleGoogle Scholar
  66. Meije Y, Piersimoni C, Torre-Cisneros J, Dilektasli AG, Aguado JM. Mycobacterial infections in solid organ transplant recipients. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2014;20(Suppl 7):89–101. https://doi.org/10.1111/1469-0691.12641. ArticleGoogle Scholar
  67. Pennington KM, Kennedy CC, Chandra S, Lauzardo M, Brito MO, Griffith DE, et al. Management and diagnosis of tuberculosis in solid organ transplant candidates and recipients: expert survey and updated review(). Journal of clinical tuberculosis and other mycobacterial diseases. 2018;11:37–46. https://doi.org/10.1016/j.jctube.2018.04.001. ArticlePubMedPubMed CentralGoogle Scholar
  68. MacLean E, Kohli M, Weber SF, Suresh A, Schumacher SG, Denkinger CM et al. Advances in molecular diagnosis of tuberculosis. Journal of clinical microbiology. 2020;58(10). doi:https://doi.org/10.1128/jcm.01582-19.
  69. Organization WH. Next-generation Xpert® MTB/RIF Ultra assay recommended by WHO. 2017. https://www.who.int/tb/features_archive/Xpert-Ultra/en/. Accessed 18-04-2021 2021.
  70. Cazabon D, Suresh A, Oghor C, Qin ZZ, Kik SV, Denkinger CM, et al. Implementation of Xpert MTB/RIF in 22 high tuberculosis burden countries: are we making progress? European Respiratory Journal. 2017;50(2):1700918. https://doi.org/10.1183/13993003.00918-2017. ArticleGoogle Scholar
  71. Cazabon D, Pande T, Kik S, Van Gemert W, Sohn H, Denkinger C et al. Market penetration of Xpert MTB/RIF in high tuberculosis burden countries: a trend analysis from 2014-2016 [version 2; peer review: 4 approved]. Gates Open Research. 2018;2(35). doi:https://doi.org/10.12688/gatesopenres.12842.2.
  72. Zhang XF, Lv Y, Xue WJ, Wang B, Liu C, Tian PX, et al. Mycobacterium tuberculosis infection in solid organ transplant recipients: experience from a single center in China. Transplantation proceedings. 2008;40(5):1382–5. https://doi.org/10.1016/j.transproceed.2008.01.075. ArticleCASPubMedGoogle Scholar
  73. Rahimifard N, Mahmoudi S, Mamishi S, Pourakbari B. Prevalence of latent tuberculosis infection in transplant candidates: a systematic review and meta-analysis. Microbial pathogenesis. 2018;125:401–10. https://doi.org/10.1016/j.micpath.2018.09.040. ArticlePubMedGoogle Scholar
  74. Morris MI, Daly JS, Blumberg E, Kumar D, Sester M, Schluger N, et al. Diagnosis and management of tuberculosis in transplant donors: a donor-derived infections consensus conference report. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2012;12(9):2288–300. https://doi.org/10.1111/j.1600-6143.2012.04205.x. ArticleCASGoogle Scholar
  75. Aguado JM, Torre-Cisneros J, Fortún J, Benito N, Meije Y, Doblas A, et al. Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2009;48(9):1276–84. https://doi.org/10.1086/597590. ArticleGoogle Scholar
  76. Santoro-Lopes G, Subramanian AK, Molina I, Aguado JM, Rabagliatti R, Len O. Tuberculosis recommendations for solid organ transplant recipients and donors. Transplantation. 2018;102(2S):S60–S5. https://doi.org/10.1097/tp.0000000000002014. ArticlePubMedGoogle Scholar
  77. Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016;63(7):e147–e95. https://doi.org/10.1093/cid/ciw376. ArticleGoogle Scholar
  78. Park YS, Choi JY, Cho CH, Chang KH, Song YG, Kim YS, et al. Clinical outcomes of tuberculosis in renal transplant recipients. Yonsei medical journal. 2004;45(5):865–72. https://doi.org/10.3349/ymj.2004.45.5.865. ArticlePubMedGoogle Scholar
  79. Organization WH. WHO announces updated definitions of extensively drug-resistant tuberculosis. 2021. https://www.who.int/news/item/27-01-2021-who-announces-updated-definitions-of-extensively-drug-resistant-tuberculosis#:~:text=*%20MDR%2DTB%3A%20Resistance%20of,for%20the%20treatment%20of%20TB. Accessed 17-04-2021 2021.
  80. Huaman MA, Brawley R, Ashkin D. Multidrug-resistant tuberculosis in transplant recipients: case report and review of the literature. Transplant infectious disease: an official journal of the Transplantation Society. 2017;19(2). doi:10.1111/tid.12672.
  81. Organization WH. WHO consolidated guidelines on tuberculosis, module 4: treatment - drug-resistant tuberculosis treatment. 2020. https://www.who.int/publications/i/item/9789240007048. Accessed 28-Feb-21 2021.
  82. Yin J, Yuan J, Hu Y, Wei X. Association between directly observed therapy and treatment outcomes in multidrug-resistant tuberculosis: a systematic review and meta-analysis. PloS one. 2016;11(3):e0150511. https://doi.org/10.1371/journal.pone.0150511. ArticleCASPubMedPubMed CentralGoogle Scholar
  83. Sterling TR, Lehmann HP, Frieden TR. Impact of DOTS compared with DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths: decision analysis. BMJ (Clinical research ed). 2003;326(7389):574. doi:https://doi.org/10.1136/bmj.326.7389.574.
  84. Marques ID, Azevedo LS, Pierrotti LC, Caires RA, Sato VA, Carmo LP, et al. Clinical features and outcomes of tuberculosis in kidney transplant recipients in Brazil: a report of the last decade. Clinical transplantation. 2013;27(2):E169–76. https://doi.org/10.1111/ctr.12077. ArticlePubMedGoogle Scholar
  85. Jeong JC, Koo TY, Jeon HJ, Park HC, Ryu HJ, Lee JP, et al. Utility of QuantiFERON-TB assay for prediction of tuberculosis development in kidney transplant patients in an intermediate-tuberculosis-burden country: lack of evidence for enhanced prediction for short-term tuberculosis development. Transplantation proceedings. 2014;46(2):583–7. https://doi.org/10.1016/j.transproceed.2013.11.108. ArticleCASPubMedGoogle Scholar
  86. Screening for tuberculosis and tuberculosis infection in high-risk populations. Recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR Recommendations and reports: morbidity and mortality weekly report Recommendations and reports. 1995;44(Rr-11):19-34.
  87. Shu CC, Tsai MK, Lin SW, Wang JY, Yu CJ, Lee CY. Latent tuberculosis infection increases in kidney transplantation recipients compared with transplantation candidates: a neglected perspective in tuberculosis control. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2020;71(4):914–23. https://doi.org/10.1093/cid/ciz851. ArticleGoogle Scholar
  88. Dodani S, Nasim A, Aziz T, Naqvi A. The efficacy of isoniazid prophylaxis in renal transplant recipients in a high TB burden country. medRxiv. 2021:2021.02.28.21252563. doi:https://doi.org/10.1101/2021.02.28.21252563.
  89. Joo DJ, Kim BS, Kim SJ, Huh KH, Kim MS, Ju MK et al. Risk factors and characteristics of post-transplant tuberculosis in an endemic area. Annals of transplantation. 2013;18:163-73. doi:https://doi.org/10.12659/aot.883882.
  90. Adamu B, Abdu A, Abba AA, Borodo MM, Tleyjeh IM. Antibiotic prophylaxis for preventing post solid organ transplant tuberculosis. The Cochrane database of systematic reviews. 2014;2014(3):Cd008597. doi:https://doi.org/10.1002/14651858.CD008597.pub2.
  91. Maung Myint T, Rogerson TE, Noble K, Craig JC, Webster AC. Tests for latent tuberculosis in candidates for solid organ transplantation: a systematic review and meta-analysis. Clinical transplantation. 2019;33(8):e13643. https://doi.org/10.1111/ctr.13643. ArticlePubMedGoogle Scholar
  92. Lyu J, Lee SG, Hwang S, Lee SO, Cho OH, Chae EJ, et al. Chest computed tomography is more likely to show latent tuberculosis foci than simple chest radiography in liver transplant candidates. Liver transplantation: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2011;17(8):963–8. https://doi.org/10.1002/lt.22319. ArticleGoogle Scholar
  93. Aspler A, Long R, Trajman A, Dion MJ, Khan K, Schwartzman K, et al. Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB. Thorax. 2010;65(7):582–7. https://doi.org/10.1136/thx.2009.125054. ArticlePubMedGoogle Scholar
  94. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. The New England journal of medicine. 2011;365(23):2155–66. https://doi.org/10.1056/NEJMoa1104875. ArticleCASPubMedGoogle Scholar
  95. Langendam MW, Tiemersma EW, van der Werf MJ, Sandgren A. Adverse events in healthy individuals and MDR-TB contacts treated with anti-tuberculosis drugs potentially effective for preventing development of MDR-TB: a systematic review. PloS one. 2013;8(1):e53599. https://doi.org/10.1371/journal.pone.0053599. ArticleCASPubMedPubMed CentralGoogle Scholar
  96. Health NIo. NIH launches large TB prevention trial for people exposed to multidrug-resistant TB. 2019. https://www.nih.gov/news-events/news-releases/nih-launches-large-tb-prevention-trial-people-exposed-multidrug-resistant-tb. Accessed 18-04-2021 2021.
  97. Hermans SM, Grant AD, Chihota V, Lewis JJ, Vynnycky E, Churchyard GJ, et al. The timing of tuberculosis after isoniazid preventive therapy among gold miners in South Africa: a prospective cohort study. BMC Medicine. 2016;14(1):45. https://doi.org/10.1186/s12916-016-0589-3. ArticleCASPubMedPubMed CentralGoogle Scholar
  98. Organization WH. WHO guidelines on tuberculosis infection prevention and control. 2019. https://apps.who.int/iris/bitstream/handle/10665/311259/9789241550512-eng.pdf. Accessed 18-04-2021 2021.
  99. Banach DB, Seville MTA, Kusne S. Infection prevention and control issues after solid organ transplantation. Transplant infections: Fourth Edition. 2016:843–67. https://doi.org/10.1007/978-3-319-28797-3_46.
  100. Allegranzi B, Bagheri Nejad S, Combescure C, Graafmans W, Attar H, Donaldson L et al. Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. Lancet (London, England). 2011;377(9761):228-41. doi:https://doi.org/10.1016/s0140-6736(10)61458-4.
  101. Verkuijl S, Middelkoop K. Protecting our front-liners: occupational tuberculosis prevention through infection control strategies. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2016;62(Suppl 3):S231–7. https://doi.org/10.1093/cid/civ1184. ArticleGoogle Scholar
  102. Fox GJ, Schaaf HS, Mandalakas A, Chiappini E, Zumla A, Marais BJ. Preventing the spread of multidrug-resistant tuberculosis and protecting contacts of infectious cases. Clinical Microbiology and Infection. 2017;23(3):147–53. https://doi.org/10.1016/j.cmi.2016.08.024. ArticleCASPubMedGoogle Scholar
  103. Bamford A, Dixon G, Klein N, Marks SD, Ritz N, Welch SB et al. Preventing tuberculosis in paediatric kidney transplant recipients: is there a role for BCG immunisation pre-transplantation in low tuberculosis incidence countries? Pediatric nephrology (Berlin, Germany). 2020. doi:https://doi.org/10.1007/s00467-020-04844-5.
  104. Mangtani P, Abubakar I, Ariti C, Beynon R, Pimpin L, Fine PE, et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2014;58(4):470–80. https://doi.org/10.1093/cid/cit790. ArticleGoogle Scholar
  105. Roy A, Eisenhut M, Harris RJ, Rodrigues LC, Sridhar S, Habermann S et al. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. BMJ (Clinical research ed). 2014;349:g4643. doi:https://doi.org/10.1136/bmj.g4643.
  106. Bakkaloğlu SA, Özdemir Atikel Y, Paglialonga F, Stefanidis CJ, Askiti V, Vidal E, et al. Vaccination practices in pediatric dialysis patients across Europe. A European Pediatric Dialysis Working Group and European Society for Pediatric Nephrology Dialysis Working Group Study. Nephron. 2018;138(4):280–6. https://doi.org/10.1159/000485398. ArticlePubMedGoogle Scholar
  107. Venkataraman A, Yusuff M, Liebeschuetz S, Riddell A, Prendergast AJ. Management and outcome of Bacille Calmette-Guérin vaccine adverse reactions. Vaccine. 2015;33(41):5470–4. https://doi.org/10.1016/j.vaccine.2015.07.103. ArticlePubMedPubMed CentralGoogle Scholar
  108. Casanova JL, Jouanguy E, Lamhamedi S, Blanche S, Fischer A. Immunological conditions of children with BCG disseminated infection. Lancet (London, England). 1995;346(8974):581. doi:https://doi.org/10.1016/s0140-6736(95)91421-8.
  109. Hesseling AC, Johnson LF, Jaspan H, Cotton MF, Whitelaw A, Schaaf HS, et al. Disseminated bacille Calmette-Guérin disease in HIV-infected South African infants. Bulletin of the World Health Organization. 2009;87(7):505–11. https://doi.org/10.2471/blt.08.055657. ArticleCASPubMedPubMed CentralGoogle Scholar
  110. Lin WL, Chiu NC, Lee PH, Huang AS, Huang FY, Chi H, et al. Management of Bacillus Calmette-Guérin osteomyelitis/osteitis in immunocompetent children-a systematic review. Vaccine. 2015;33(36):4391–7. https://doi.org/10.1016/j.vaccine.2015.07.039. ArticlePubMedGoogle Scholar
  111. Bernatowska EA, Wolska-Kusnierz B, Pac M, Kurenko-Deptuch M, Zwolska Z, Casanova JL, et al. Disseminated bacillus Calmette-Guérin infection and immunodeficiency. Emerging infectious diseases. 2007;13(5):799–801. https://doi.org/10.3201/eid1305.060865. ArticlePubMedPubMed CentralGoogle Scholar
  112. Kinoshita N, Shoji K, Funaki T, Fukuda A, Sakamoto S, Kasahara M, et al. Safety of BCG vaccination in pediatric liver transplant recipients. Transplantation. 2018;102(4):e125. https://doi.org/10.1097/tp.0000000000002103. ArticlePubMedGoogle Scholar
  113. Ziegler J, Ho J, Gibson IW, Nayak JG, Stein M, Walkty A, et al. Disseminated Mycobacterium bovis infection post-kidney transplant following remote intravesical BCG therapy for bladder cancer. Transplant infectious disease: an official journal of the Transplantation Society. 2018;20(5):e12931. https://doi.org/10.1111/tid.12931. ArticleCASGoogle Scholar
  114. Danziger-Isakov L, Kumar D. Vaccination in solid organ transplantation. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2013;13(Suppl 4):311–7. https://doi.org/10.1111/ajt.12122. ArticleCASGoogle Scholar
  115. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2014;58(3):309–18. https://doi.org/10.1093/cid/cit816. ArticleGoogle Scholar
  116. Tebruegge M, Ritz N, Curtis N, Shingadia D. Diagnostic tests for childhood tuberculosis: past imperfect, present tense and future perfect? The Pediatric infectious disease journal. 2015;34(9):1014–9. https://doi.org/10.1097/inf.0000000000000796. ArticlePubMedGoogle Scholar

Funding

No funding was obtained for this study.